Facial Melasma Clinical Trial
Official title:
Efficacy and Safety of a 4% Hydroquinone Cream (Melanoderm 4%) for the Treatment of Melasma: a Randomized Controlled Split-face Study
To assess the ability of a new 4% Hydroquinone formulation (Melanoderm 4% Crema) to reduce
melasma on the face, using a split-face randomization design, evaluating the MASI Score from
baseline to week 4 and week 8, in both half-faces receiving active treatment vs. placebo.
To assess the tolerance of a new 4% Hydroquinone formulation (Melanoderm 4% Crema) on the
face.
To assess patients' satisfaction regarding Melanoderm 4% Crema after 8 weeks.
n/a